TFF
IDXX icon

The Family Firm’s Idexx Laboratories IDXX Stock Holding History

The Family Firm’s Portfolio IDXX Stock Details IDXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-37
Closed -$18K – 500
2024
Q2 		$18K Buy
+37
New +$18.6K ﹤0.01% 585

Other funds holding IDXX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

The Family Firm's IDXX Position: Q3 2024 in Review

The Family Firm sold out of Idexx Laboratories (IDXX) in Q3 2024, closing a stake of 37 shares — an estimated $18K sold.

The Family Firm first reported a position in IDXX in Q2 2024 and held it in 1 quarter. The position peaked at $18K in Q2 2024. 1,116 funds tracked by Wall St. Rank hold IDXX as of Q3 2024.

  • The Family Firm reported no remaining Idexx Laboratories position as of Q3 2024 after selling out during the quarter.
  • The Family Firm sold 37 Idexx Laboratories shares in Q3 2024, an estimated $18K.
  • The Family Firm first reported a position in Idexx Laboratories in Q2 2024 and held it in 1 quarter.
  • The Family Firm's Idexx Laboratories position peaked at $18K in Q2 2024.
  • 1,116 funds tracked by Wall St. Rank held Idexx Laboratories as of Q3 2024.

Based on The Family Firm's 13F filing for Q3 2024, filed 17 Oct 2024.